MA50093B1 - Composé pentacyclique - Google Patents
Composé pentacycliqueInfo
- Publication number
- MA50093B1 MA50093B1 MA50093A MA50093A MA50093B1 MA 50093 B1 MA50093 B1 MA 50093B1 MA 50093 A MA50093 A MA 50093A MA 50093 A MA50093 A MA 50093A MA 50093 B1 MA50093 B1 MA 50093B1
- Authority
- MA
- Morocco
- Prior art keywords
- pentacyclic compound
- pentacyclic
- compound
- formulas
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des composés représentés par les formules (i) à (vi) ou des sels pharmaceutiquement acceptables de ceux-ci :
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017172169 | 2017-09-07 | ||
| PCT/JP2018/032797 WO2019049869A1 (fr) | 2017-09-07 | 2018-09-05 | Composé pentacyclique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50093A MA50093A (fr) | 2021-05-05 |
| MA50093B1 true MA50093B1 (fr) | 2022-05-31 |
Family
ID=65517037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50093A MA50093B1 (fr) | 2017-09-07 | 2018-09-05 | Composé pentacyclique |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US10239889B1 (fr) |
| EP (1) | EP3680243B1 (fr) |
| JP (1) | JP6557441B1 (fr) |
| KR (1) | KR102307738B1 (fr) |
| CN (1) | CN111051316B (fr) |
| AR (1) | AR112788A1 (fr) |
| AU (1) | AU2018330578B2 (fr) |
| BR (1) | BR112020003197A2 (fr) |
| CA (1) | CA3072740A1 (fr) |
| CL (1) | CL2020000376A1 (fr) |
| CO (1) | CO2020001471A2 (fr) |
| CY (1) | CY1125355T1 (fr) |
| DK (1) | DK3680243T3 (fr) |
| ES (1) | ES2903172T3 (fr) |
| HR (1) | HRP20220019T1 (fr) |
| HU (1) | HUE056791T2 (fr) |
| IL (1) | IL272652B (fr) |
| JO (1) | JOP20200030A1 (fr) |
| LT (1) | LT3680243T (fr) |
| MA (1) | MA50093B1 (fr) |
| MD (1) | MD3680243T2 (fr) |
| MX (1) | MX2020001786A (fr) |
| PH (1) | PH12020500341A1 (fr) |
| PL (1) | PL3680243T3 (fr) |
| PT (1) | PT3680243T (fr) |
| RS (1) | RS62796B1 (fr) |
| RU (1) | RU2754557C1 (fr) |
| SG (1) | SG11202001240XA (fr) |
| SI (1) | SI3680243T1 (fr) |
| TW (1) | TWI707859B (fr) |
| UA (1) | UA125940C2 (fr) |
| WO (1) | WO2019049869A1 (fr) |
| ZA (1) | ZA202000970B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018329840A1 (en) | 2017-09-07 | 2020-03-19 | Augusta University Research Institute, Inc. | Specific Akt3 activator and uses thereof |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| EA202191966A1 (ru) | 2019-03-05 | 2021-12-08 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пентациклическое гетероциклическое соединение |
| AU2020233452A1 (en) * | 2019-03-05 | 2021-09-02 | Eisai R&D Management Co., Ltd. | Salt of pentacyclic compound and crystals thereof |
| EP4069369A4 (fr) * | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | Composés cycliques et leurs procédés d'utilisation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187306A (en) | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
| DD258234A1 (de) * | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
| RU2117670C1 (ru) * | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
| TW197442B (fr) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| KR100203456B1 (ko) * | 1995-06-20 | 1999-06-15 | 한승수 | 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제 |
| FR2779652B1 (fr) * | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| EP1807432A1 (fr) * | 2004-10-20 | 2007-07-18 | F. Hoffmann-Roche AG | Dérivés de benzodiazépine à substitution halogène |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| US8192080B2 (en) | 2007-01-23 | 2012-06-05 | Tsi Technologies Llc | Microwire-controlled autoclave and method |
-
2018
- 2018-09-05 JO JOP/2020/0030A patent/JOP20200030A1/ar unknown
- 2018-09-05 JP JP2019516726A patent/JP6557441B1/ja active Active
- 2018-09-05 RS RS20220015A patent/RS62796B1/sr unknown
- 2018-09-05 KR KR1020207004232A patent/KR102307738B1/ko active IP Right Grant
- 2018-09-05 CN CN201880053052.1A patent/CN111051316B/zh active Active
- 2018-09-05 UA UAA202000934A patent/UA125940C2/uk unknown
- 2018-09-05 WO PCT/JP2018/032797 patent/WO2019049869A1/fr unknown
- 2018-09-05 AR ARP180102517A patent/AR112788A1/es unknown
- 2018-09-05 MD MDE20200725T patent/MD3680243T2/ro unknown
- 2018-09-05 TW TW107131095A patent/TWI707859B/zh active
- 2018-09-05 LT LTEPPCT/JP2018/032797T patent/LT3680243T/lt unknown
- 2018-09-05 ES ES18853415T patent/ES2903172T3/es active Active
- 2018-09-05 PT PT188534150T patent/PT3680243T/pt unknown
- 2018-09-05 SI SI201830467T patent/SI3680243T1/sl unknown
- 2018-09-05 MX MX2020001786A patent/MX2020001786A/es unknown
- 2018-09-05 US US16/122,116 patent/US10239889B1/en active Active
- 2018-09-05 HR HRP20220019TT patent/HRP20220019T1/hr unknown
- 2018-09-05 HU HUE18853415A patent/HUE056791T2/hu unknown
- 2018-09-05 EP EP18853415.0A patent/EP3680243B1/fr active Active
- 2018-09-05 BR BR112020003197-6A patent/BR112020003197A2/pt unknown
- 2018-09-05 MA MA50093A patent/MA50093B1/fr unknown
- 2018-09-05 SG SG11202001240XA patent/SG11202001240XA/en unknown
- 2018-09-05 AU AU2018330578A patent/AU2018330578B2/en active Active
- 2018-09-05 IL IL272652A patent/IL272652B/en unknown
- 2018-09-05 DK DK18853415.0T patent/DK3680243T3/da active
- 2018-09-05 CA CA3072740A patent/CA3072740A1/fr active Pending
- 2018-09-05 RU RU2020106798A patent/RU2754557C1/ru active
- 2018-09-05 PL PL18853415T patent/PL3680243T3/pl unknown
-
2020
- 2020-02-11 CO CONC2020/0001471A patent/CO2020001471A2/es unknown
- 2020-02-13 CL CL2020000376A patent/CL2020000376A1/es unknown
- 2020-02-14 ZA ZA2020/00970A patent/ZA202000970B/en unknown
- 2020-02-14 PH PH12020500341A patent/PH12020500341A1/en unknown
-
2022
- 2022-01-10 CY CY20221100025T patent/CY1125355T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50093B1 (fr) | Composé pentacyclique | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| BR112017019286A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável deste | |
| WO2019132561A8 (fr) | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| MA46337B1 (fr) | Composé de pyridine | |
| EA201792021A1 (ru) | Ингибитор jak | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| MA40302A1 (fr) | Dérivés de carbazole | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MA44781B1 (fr) | Composé hétérocyclique condensé | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MA38991A1 (fr) | Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt | |
| EA201791596A1 (ru) | Пиразоловые соединения | |
| AR125853A2 (es) | Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico |